Loading stock data…
VCYT
$49.24+1.97 (+4.17%)
After Hours$49.77+0.53 (+1.08%)· Last close Jun 9
Veracyte, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Veracyte, Inc. in the Healthcare sector is trading at $49.24. Wall Street consensus targets $49.10 (10 analysts), implying a -0.3% move over the next 12 months. The stock is currently near its 52-week high of $50.71, remaining 30.5% above its 200-day moving average. On fundamentals, Piotroski 8/9 indicates strong financial quality, Altman Z in the distress zone. The Whystock Score of 85/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side consensus broadly in line with current price
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$49.24
Potential Downside
0%
Whystock Fair Value$49.24
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus10 analysts
Buy
Mean target$49.10-0.3%
Range$37.00 – $57.00
Fundamentals
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Dec...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
6.55%
Volume
Today's trading volume
986,829
Recent News
How Veracyte (VCYT) Investors Can Read The Latest Unchanged Analyst Call
Veracyte’s latest analyst update comes with no change in the price target, which can be just as informative as a revision. With fresh information in hand but no shift in the target, the message for you as an investor is more about stability than surprise. Read on to see how to interpret this kind of unchanged call and how to keep tracking the story as the narrative around Veracyte continues to evolve. Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies...
Why Is Veracyte (VCYT) Up 18.2% Since Last Earnings Report?
Veracyte (VCYT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Is it Worth Retaining Veracyte Stock in Your Portfolio for Now?
VCYT gains from strong Afirma and Decipher test growth, but macro pressures and competition pose risks. See what may shape its next move.
Veracyte Stock Surges 65.8% in a Year: What's Driving the Rally?
VCYT jumps 65.8% in a year as Afirma and Decipher volumes surge, guidance lifts, and TrueMRD nears launch with $439M cash and no debt.
Here's How Much You'd Have If You Invested $1000 in Veracyte a Decade Ago
Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.